These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Clinical pharmacokinetics of sulphasalazine. Das KM; Dubin R Clin Pharmacokinet; 1976; 1(6):406-25. PubMed ID: 15752 [TBL] [Abstract][Full Text] [Related]
30. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group. Rutgeerts P Aliment Pharmacol Ther; 1989 Apr; 3(2):183-91. PubMed ID: 2577483 [TBL] [Abstract][Full Text] [Related]
31. [Unwanted side-effects in using mesalazine (5-aminosalicylic acid) during radiotherapy]. Freund U; Schölmerich J; Siems H; Kluge F; Schäfer HE; Wannenmacher M Strahlenther Onkol; 1987 Oct; 163(10):678-80. PubMed ID: 3313776 [TBL] [Abstract][Full Text] [Related]
32. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. Nilsson A; Danielsson A; Löfberg R; Benno P; Bergman L; Fausa O; Florholmen J; Karvonen AL; Kildebo S; Kollberg B Am J Gastroenterol; 1995 Mar; 90(3):381-7. PubMed ID: 7872274 [TBL] [Abstract][Full Text] [Related]
33. [The effect of sulphasalazine, sulphapyridine, 5-aminosalicylic acid and prednisolone on superoxide production by human polymorphonuclear leukocytes: in vitro studies]. Ide T Nihon Shokakibyo Gakkai Zasshi; 1986 Sep; 83(9):2090. PubMed ID: 3025481 [No Abstract] [Full Text] [Related]
34. The scavenging of oxidants by sulphasalazine and its metabolites. A possible contribution to their anti-inflammatory effects? Aruoma OI; Wasil M; Halliwell B; Hoey BM; Butler J Biochem Pharmacol; 1987 Nov; 36(21):3739-42. PubMed ID: 2890355 [TBL] [Abstract][Full Text] [Related]